Diterpenoid derivatives as anticancer agents

Overview

This invention relates to a group of derivatives synthesized based on the ent-kaurane diterpenoid flexicaulin A (FA). These compounds can be used as a medicament for the treatment of tumours or cancers.

Commercialisation opportunities

technology licensing agreement

Problem addressed

Chemotherapy resistance is a major concern in the medical management of many cancer patients. Thus, development of new and potent anticancer drugs are urgently needed. The compounds of this invention are based on plant-derived natural compound, that can be used for cancers.

Innovation

This group of compounds demonstrated anti-proliferative effect in common human cancer cell lines, including colorectal, skin and pancreatic cancer.

Key impact

Paclitaxel (PTX) is an approved chemotherapy drug used to treat a number of types of cancer. It is also a natural compound. In the animal study, the present invention's compounds demonstrated a better anti-cancer activity while having a similar toxicity result with PTX.

Application

The compound has potential to develop into pharmaceutical products e.g. anti-cancer drug for colorectal carcinoma.

Patent

US Patent No. US 9,795,589
US Patent No. US 10,493,056
China Patent No. ZL 2017 8 0054194.5

Hong Kong Baptist University (HKBU)

Aspiring to be a leading, research-led, liberal arts University in Asia, Hong Kong Baptist University is committed to conducting world-leading investigations that extends the frontiers of knowledge, tackles global challenges and benefits the community at home and abroad.

Pursuing research excellence is one of the priorities of the University’s Institutional Strategic Plan 2018-2028. The University keeps enhancing its capacity and strength to produce world-class research with an aim to bring significant impact to the society.

Enquiry